Neovasc — Investor Presentation (December 2011)
22 slides from Neovasc's investor presentation, December 2011
Slide 1: Neovasc Inc.
Neovasc Inc. Alexei Marko, CEO December 2011
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo
Slide 3: Neovasc at-a-Glance
Neovasc at-a-Glance • Focused on innovative products to treat heart disease and related conditions • Three key product lines under development with large growth potential: 1. Neovasc Reducer™ for treatment of refractory angina (CE marked) 2. Implantable biological tissue and services for transcathet
Slide 4: Reducer Product: Treats Refractory Angina
Reducer Product Treats Refractory Angina • Inadequate blood flow to heart muscle that cannot be managed through conventional drug, catheter or surgical therapy • Causes constant & severe heart pain • Large & growing population of untreatable patients – Improved cardiac care Æ less mortality & more p
Slide 5: Reducer Market Opportunity
Reducer Market Opportunity Estimated selling price $2,000-$3,000 • ~ 2,000,000 existing “no option” refractory angina patients in US & Europe • ~400,000 new “no option” patients diagnosed annually • ~1,000,000 patients/year treated for “recurrent” angina 5
Slide 6: Reducer Method of Action
Reducer Method of Action Reducer modulates outflow of blood from coronary veins, increasing blood flow to ischemic areas Blood flow takes path of Venous back pressure least resistance causes more uniform • Majority of blood flows distribution of blood around ischemic flow through heart areas muscle
Slide 7: Reducer Procedure
Reducer Procedure • Based on 1950’s surgical procedure (Beck Procedure) • Reported excellent results but is no longer performed due to surgery’s invasiveness • Neovasc Reducer achieves same narrowing using modern non-surgical catheter-based techniques • Reducer procedure takes ~20 minutes; patient d
Slide 8: Reducer Clinical Results
Reducer Clinical Results Compelling clinical data from 1st human trial (15 patients, 3 centers) • 6-month data published in May 2007 JACC demonstrated safety & significant improvement of angina symptoms • 3-year follow-up data confirms excellent long-term safety & treatment durability (presented at
Slide 9: COSIRA Trial
Reducer COSIRA Trial COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) Double-blind, randomized, sham-controlled, multicenter, prospective trial • 124 patients • Randomized 1:1 to blinded treatment & sham control arms • Primary endpoint: Efficacy @ 6-months • Sites in Belgium, Canad
Slide 10: Reducer Case Study
Reducer Case Study Patient: 69 year old female, with multiple prior revascularizations (CABG, multiple stents, transcatheter aortic valve replacement). Suffering from severe refractory angina with routine activities such as walking short distances or climbing stairs Procedure: Neovasc Reducer implan
Slide 11: Reducer Case Study: Results
Reducer Case Study Very Promising Results 6 months after implantation* Baseline 6 month FU CCS Class III I (Angina Score) Functional Class Severe angina pain Rides her bicycle when walking short 30-60 min each day distances or climbing stairs Dobutamine Echo Severe postero- NO ischemia lateral ische
Slide 12: Reducer Key Opinion Leaders
Reducer Key Opinion Leaders Leaders in interventional cardiology & refractory angina are working on Reducer program • Dr. Shmuel Banai (Tel Aviv Souraski Medical Center) • Dr. Elazer Edelman (Harvard – MIT, Cambridge) • Dr. Tim Henry (Minneapolis Heart Institute) • Dr. Marc Jolicoeur (Montreal Heart
Slide 13: Reducer Commercialization Timeline
Reducer Commercialization Timeline 1. Europe: – CE mark received November 2011 – Continue COSIRA trial enrollment – Collect additional clinical data through patient Registries being initiated in Europe, Israel and Canada – Launch with distribution partner(s) later 2012 2. US: FDA IDE trial to be ini
Slide 14: Biological Tissue Products
Biological Tissue Products • Proprietary process creates implantable, biocompatible tissue that retains strength & physical characteristics of natural tissue • Developed specifically for fabricating surgical heart valves • 20+ year implant history • FDA-cleared, CE-marked, EDQM certified • State-of-
Slide 15: Biological Tissue Business
Biological Tissue Business Neovasc provides: • Custom biological tissue to wide range of industry partners for use in their devices such as surgical patches and transcatheter heart valves • Development & prototyping services for devices incorporating pericardial tissue • Pilot & commercial manufactu
Slide 16: Rapid Growth in Heart Valve Applications
Rapid Growth in Heart Valve Applications Neovasc is leading independent supplier of biological leaflet material & related services to companies developing transcatheter heart valves • Projected 2011 worldwide sales of ~$600M from first generation transcatheter aortic valve products (Sapien, Corevalv
Slide 17: Pipeline Projects - Mitral Regurgitation
Pipeline Projects - Mitral Regurgitation Diseased mitral valve allows blood leakage back into left atrium (“mitral regurgitation” or “MR”) can lead to heart failure & death – ~4 million US patients with significant MR – ~600,000 new MR patients annually in US & Europe – Conventional surgical treatme
Slide 18: Pipeline Projects – Tiara
Pipeline Projects – Tiara™ Neovasc is developing Tiara™-- a novel transcatheter device for the treatment of mitral regurgitation. Tiara is delivered through apex of heart or transfemorally to replace diseased mitral valve • Patent applications filed covering apparatus & methodology • Refined prototy
Slide 19: 2011 / 2012: Looking Forward
2011 / 2012: Looking Forward Continued growth in revenues from tissue business (2011 target $5M) • Expect steady growth in 2012 with upside potential as customers’ products are commercialized Complete COSIRA trial for Reducer and launch in Europe • Controlled EU release in near term to build clinica
Slide 20: Capitalization & Trading
Capitalization & Trading • 45.7m (issued and outstanding) Shares outstanding • 54.5m (fully diluted) Public listing • TSXV: NVC • Frost Group • Gagnon Securities Key investors • OPKO Health • Company directors and management • August 2011 financing oversubscribed (raised $4.7M) Cash requirements • F
Slide 21: Investment Summary
Investment Summary 1. Established tissue products business cash flow positive & growing; easily scalable to meet rising demand 2. Neovasc Reducer™ at point of commercialization to treat serious cardiovascular condition with no current therapy 3. Tiara™ program targets high potential transcatheter mi
Slide 22: Thank you
Thank you 22